NEW YORK—Jefferies initiated coverage on Freenome Inc. (NASDAQ: FRNM) with a Buy rating and a $17 price target, giving the cancer screening company its first major Wall Street endorsement. The stock trades at $11.56, putting the gap to Jefferies' target at roughly 47 percent.
Freenome builds blood-based tests designed to detect cancer early. The firm competes in a market where liquid biopsy—blood-based cancer screening offered as an alternative to invasive tissue testing—has drawn intense investor interest. Jefferies singled out the company's screening potential as the primary investment case.
The initiation comes as the broader cancer screening sector draws fresh analyst attention. Jefferies also participated in a conference appearance by Guardant Health, a more established liquid biopsy player, where analysts probed growth prospects in cancer screening. Guardant discussed its Reveal Ultra product rollout as a near-term revenue driver, suggesting the firm sees the cancer screening space as actively expanding rather than maturing.
Freenome sits at an earlier stage than Guardant. At $11.56, the stock carries a market valuation well below the large-cap diagnostics names, which is precisely the risk-reward Jefferies is underwriting with a Buy. A move to $17 would represent a near-doubling of the company's market value from current levels.
The Jefferies initiation carries real risk. Clinical-stage screening companies depend on FDA clearance and reimbursement decisions from major insurers—two variables that set the actual commercial timeline, not analyst price targets. Jefferies did not publish a specific timeline for those milestones in available material, but the $17 target implies the firm expects meaningful progress within a 12-month horizon.
Jefferies has been active across the oncology space in recent weeks. The firm upgraded Tango Therapeutics (NASDAQ: TNGX) to Buy from Hold and raised its price target to $60 from $27 after cancer trial data came in. Tango trades at $30.14 and has risen 486 percent over the past year. That upgrade shows Jefferies is willing to make high-conviction calls in oncology when data supports it—the Freenome initiation fits the same pattern, though Freenome is a screening play rather than a therapeutic one.
The oncology analyst desk at Jefferies also upgraded Abivax, a French biotech, after new drug data gave the analyst renewed confidence. Ten of 12 analysts covering Abivax rate it a buy or strong buy, according to LSEG data. The cluster of Jefferies upgrades and initiations across oncology names suggests a deliberate sector call, not a series of isolated stock picks.
For Freenome specifically, the investment case rests on the size of the addressable market in early cancer detection. Blood-based screening tests that can flag cancer before symptoms appear represent one of the largest unmet needs in preventive medicine. The commercial question is whether payers will reimburse the tests at a price point that supports a viable business—a hurdle that has tripped up earlier entrants in the space.
Freenome's NASDAQ listing gives institutional investors direct equity access, and a Jefferies Buy rating will put the name on the radar of healthcare-focused funds that screen for analyst coverage as a condition of investment. The stock's thin trading history relative to established diagnostics names means a relatively small increase in institutional interest moves the price materially.
The $17 target gives traders a clean level to watch. A close above $13 on volume would confirm that the Jefferies initiation is drawing real buying rather than a one-day pop. A failure to hold $11 would suggest the market is skeptical of the screening thesis regardless of the analyst call.
